The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Bernard Doger
No Relationships to Disclose
 
Timothy Dudley Clay
Honoraria - Specialised Therapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune; Cipla; Foundation Medicine
Speakers' Bureau - AstraZeneca/MedImmune; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); BeiGene (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Exelixis (Inst); Immutep (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst)
 
Enric Carcereny
Consulting or Advisory Role - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca Spain; BMSi; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche; Takeda
 
Igor Bondarenko
No Relationships to Disclose
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen
Honoraria - Agendia; Guardant Health; Tempus
Consulting or Advisory Role - Tersera
Speakers' Bureau - Agendia; Guardant Health; Tempus
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Agendia; Guardant Health; Tempus
 
Manuel Cobo-Dols
No Relationships to Disclose
 
Martin Forster
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck; Nanobiotix; Novartis; Oxford VacMedix; Pfizer; PharmaMar; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Celgene; Guardant Health; MSD Oncology
 
Grygorii Ursol
No Relationships to Disclose
 
Gema García Ledo
Employment - Roche
Stock and Other Ownership Interests - Abbvie
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Natera
 
Laia Vilà
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Pfizer; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen
Speakers' Bureau - Janssen; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep
 
Wade Thomas Iams
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Pfizer; Chardan Consulting; Curio Science; Defined Health; G1 Therapeutics; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Outcomes Insights; Takeda
 
Christian Mueller
Employment - Immutep
Stock and Other Ownership Interests - Immutep
 
Frederic Triebel
Employment - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS